Neuronetics, Inc.
Neuronetics, Inc. (Nasdaq: STIM) develops and commercializes the NeuroStar Advanced Therapy System, a non-invasive, office-based transcranial magnetic stimulation device used to treat major depressive disorder, obsessive-compulsive disorder and anxiety symptoms associated with depression. Its customers include… From the company’s description.
Over the twelve months to Sep 30, 2026, Neuronetics, Inc. reported revenue of $159.76M, up 23.0% from a year earlier, and a net loss of $23.01M. Its operating margin was −9.4%, and operations used $8.28M in cash. In fiscal 2025, it reported revenue of $149.16M, up 99.2% from fiscal 2024, and a net loss of $39.13M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Neuronetics, Inc. does
In the company’s own words
Neuronetics, Inc. (Nasdaq: STIM) develops and commercializes the NeuroStar Advanced Therapy System, a non-invasive, office-based transcranial magnetic stimulation device used to treat major depressive disorder, obsessive-compulsive disorder and anxiety symptoms associated with depression. Its customers include psychiatrists and other healthcare providers, while its Greenbrook subsidiary operates outpatient treatment centers offering TMS and SPRAVATO therapy. Neuronetics generates revenue from treatment centers, system sales, treatment sessions, service and repair, and extended warranties, with clinic and recurring treatment-session revenue comprising the majority. The company operates as a vertically integrated mental-healthcare business following its 2024 acquisition of Greenbrook. Its U.S. commercial operations focus on selling NeuroStar systems and sessions to provider practices and providing clinical training, practice-development, reimbursement and technical support; outside the U.S., it sells through independent distributors, including an exclusive distributor in Japan. As of December 31, 2025, Greenbrook operated 93 treatment centers, and Neuronetics employed 658 people. Revenue was $149.2 million for fiscal 2025. Its website is https://neurostar.com/neuronetics/.
Company details
- Sector
- Health Care
- Industry (SIC)
- Surgical & Medical Instruments
- Headquarters
- MALVERN, PA
- Fiscal year end
- December
- CIK
- 1227636
- SIC
- 3841
Financial performance, year by year
Fiscal 2018–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Neuronetics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Neuronetics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Neuronetics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Neuronetics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Neuronetics, Inc.'s last four quarterly filings that the numbers alone won't show?”